Donald Trump unveiled a sweeping plan to lower prescription drug costs, framing it as both economic relief and a political milestone ahead of the midterms. Partnering with Pfizer, his administration will allow Medicaid programs to buy medications at internationally competitive prices, with some drugs seeing discounts of up to 80 percent.
Trump said the initiative, delayed by the pandemic, fulfills a long-standing promise to end inflated U.S. drug prices. The MFN policy links American costs to the lowest prices in other developed nations, a move he argues will create fairness without harming pharmaceutical innovation. Health officials praised the plan as a major step toward affordability.
The announcement came as Trump’s approval rating rose to 53 percent in a Rasmussen poll, reflecting renewed voter optimism. The former president framed the drug pricing overhaul as both economic reform and a matter of fairness, saying it would deliver real savings to Americans while reshaping global pharmaceutical policy.
